IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of

Confirmation No. 8950

lo SUZUKI et al.

Attorney Docket No. 2004_1390A

erial No. 10/506,469

Group Art Unit 1632

Filed September 3, 2004

Examiner Devesh Khare

NOVEL BRANCHED SIALO-SUGAR MOLECULES AND ANTIVIRAL AGENTS USING THE SAME Mail Stop: Amendment

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE

INFORMATION DISCLOSURE STATEMENT NO 23-0975

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

	[]	each U.S. Patent and U.S. Patent application publication;				
	[]	each reference previously cited in the international application PCT/; and/or				
	[]	each reference previously cited in prior parent application Serial No.				
1a.	[] This I	nformation Disclosure Statement is submitted:				
	within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or					

11/07/2006 SZEWDIE1 00000087 10506469 02 FC:1806 180.00 OP before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [X] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [X] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 2. It is hereby certified
 - a. [] that each item of information contained in this Information Disclosure

 Statement was first cited in any communication from a foreign patent office in a
 counterpart foreign application not more than three months prior to the filing of
 the Statement, or
 - b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
 4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. [] a full or partial English language translation submitted herewith,
 - b. [X] a foreign patent office (International) search report (in the English language) of record,
 - c. [] the concise explanation contained in the specification of the present application at page,
 - d. [] the concise explanation set forth in the attached English language abstract,
 - e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- 5. [] A foreign patent office search report citing one or more of the references is enclosed.
- 6. [] Statement Under 37 CFR 1.704(d)

Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign Patent Office in a counterpart application, and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Yasuo SUZUKI et al.

Ву__

Matthew M. Jacob

Registration No. 25,154

Attorney for Applicants

MJ/dlk Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 November 6, 2006

Sheet 1 of 1			INFORM <i>E</i>	ATION DISCLO	OSURE STATEMENT	IT					
, FORM PTO 1449 (m	FORM PTO 1449 (modified)				ATTY DOCKET NO. 2004_1390A SERIAL 10/506						
U.S. DEPARTMENT OF COMMERCE PATENT, AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S)				APPLICANT Yasuo SUZUKI et al.							
Date Su	(Use several sheets if necessary) Date Submitted to PTO: November 6, 2006				FILING DATE September 3, 2004				GROUP 1632		
NOV 0 6 2006 8			U	.S. PATENT D	OCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS SUBCLASS FILING DATE IF APPROPRIATE					
Missing	AA										
	AB										
	AC										
	AD										
	AE										
	AF									-	
	AG										
	АН										
	AI										
			FOR	EIGN PATENT	T DOCUMENTS						
									TRANSLA YES	ATION NO	
	AJ					<u> </u>					
	AK										
	AL										
	AM										
	AN										
		OTHER	DOCUMENT(S) (Including Author	or, Title, Date, Pertin	nent Pages	s, Etc.)	 			
	AO	J. Van Pelt et al., "Isolation and Structural Characterization of Twenty-One Sialyloligosaccharides from Galactosialidosis Urine", Biol. Chem. Hoppe Sayler, Vol. 370, pp. 191-203, March 1989.									
	AP	C. Unverzagt et al., "Chemical and Enzymatic Synthesis of Multivalent Sialoglycopeptides", Carbohydrate Research, Vol. 251, pp. 285-301, 1994.									
	AQ										
EXAMINER					DATE CONSIDERED						